News
Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers (NASDAQ:KROS)
Keros Therapeutics, Inc. (NASDAQ:KROS) is gearing up to report long-term results from its phase 2 study using KER-050 for the…
Assessing Celestica’s Near-Term Prospects Given Meteoric Rise (NYSE:CLS)
Celestica Inc. (NYSE:CLS) is still a buy or hold that requires ongoing monitoring. In my previous write-up on Celestica, I…
Verastem: Market Overreaction Creates A Dip Buying Opportunity (NASDAQ:VSTM)
Thesis overview Verastem (NASDAQ:VSTM) is a clinical-stage biotech developing small molecule inhibitors targeting the RAS signaling pathways, which are overactivated…
Today’s mortgage rates rise for 15- and 30-year terms | June 10, 2024
Our goal here at Credible Operations, Inc., NMLS Number 1681276, referred to as "Credible" below, is to give you the…
EWL: Slower Growth Relative To The S&P 500 Index
Investment Thesis iShares MSCI Switzerland ETF (NYSEARCA:EWL) owns a portfolio of about 50 stocks from Switzerland. The fund has underperformed…
Ether 2030 Price Target And Optimal Portfolio Allocations (undefined:BTC-USD)
By Matthew Sigel, Patrick Bush, Denis Zinoviev We estimate ETH's price to hit $22k by 2030 in our updated base…
Enphase Energy: Target Price Downgrade Reflects Fundamentals (NASDAQ:ENPH)
Introduction I had a 'Sell' thesis for Enphase Energy (NASDAQ:ENPH) in March. The stock delivered a 3% gain in line…
Visa Remains Strong Amid Changes In Fintech (NYSE:V)
I last covered Visa (NYSE:V) in December 2023; it was my first analysis of Visa. I put out a Buy…